228 related articles for article (PubMed ID: 25302300)
1. Magnetic resonance spectroscopy: an in vivo molecular imaging biomarker for Parkinson's disease?
Ciurleo R; Di Lorenzo G; Bramanti P; Marino S
Biomed Res Int; 2014; 2014():519816. PubMed ID: 25302300
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of proton and phosphorus MR spectroscopic imaging for early diagnosis of Parkinson's disease.
Weiduschat N; Mao X; Beal MF; Nirenberg MJ; Shungu DC; Henchcliffe C
J Neuroimaging; 2015; 25(1):105-10. PubMed ID: 24325203
[TBL] [Abstract][Full Text] [Related]
3. Whole-brain proton MR spectroscopic imaging in Parkinson's disease.
Levin BE; Katzen HL; Maudsley A; Post J; Myerson C; Govind V; Nahab F; Scanlon B; Mittel A
J Neuroimaging; 2014; 24(1):39-44. PubMed ID: 23228009
[TBL] [Abstract][Full Text] [Related]
4. Detection and application of neurochemical profile by multiple regional
Guan J; Rong Y; Wen Y; Wu H; Qin H; Zhang Q; Chen W
Brain Behav; 2017 Sep; 7(9):e00792. PubMed ID: 28948086
[TBL] [Abstract][Full Text] [Related]
5. MRS study on lentiform nucleus in idiopathic Parkinson's disease with unilateral symptoms.
Zheng XN; Zhu XC; Ruan LX; Zhang LJ; Yuan M; Shang DS; Liu Y
J Zhejiang Univ Sci; 2004 Feb; 5(2):246-50. PubMed ID: 14674041
[TBL] [Abstract][Full Text] [Related]
6. Three-dimensional magnetic resonance spectroscopic imaging in the substantia nigra of healthy controls and patients with Parkinson's disease.
Gröger A; Chadzynski G; Godau J; Berg D; Klose U
Eur Radiol; 2011 Sep; 21(9):1962-9. PubMed ID: 21484351
[TBL] [Abstract][Full Text] [Related]
7. Proton magnetic resonance spectroscopy (1H-MRS) of motor cortex and basal ganglia in de novo Parkinson's disease patients.
Lucetti C; Del Dotto P; Gambaccini G; Bernardini S; Bianchi MC; Tosetti M; Bonuccelli U
Neurol Sci; 2001 Feb; 22(1):69-70. PubMed ID: 11487206
[TBL] [Abstract][Full Text] [Related]
8. Dopamine reduction in the substantia nigra of Parkinson's disease patients confirmed by in vivo magnetic resonance spectroscopic imaging.
Gröger A; Kolb R; Schäfer R; Klose U
PLoS One; 2014; 9(1):e84081. PubMed ID: 24416192
[TBL] [Abstract][Full Text] [Related]
9. [Magnetic resonance spectroscopy in Parkinson's disease and multiple system atrophy].
Aotsuka A; Shinotoh H; Hattori T
Nihon Rinsho; 1997 Jan; 55(1):249-54. PubMed ID: 9014459
[TBL] [Abstract][Full Text] [Related]
10. Marked N-acetylaspartate and choline metabolite changes in Parkinson's disease patients with mild cognitive impairment.
Nie K; Zhang Y; Huang B; Wang L; Zhao J; Huang Z; Gan R; Wang L
Parkinsonism Relat Disord; 2013 Mar; 19(3):329-34. PubMed ID: 23238068
[TBL] [Abstract][Full Text] [Related]
11. Longitudinal study of the substantia nigra in Parkinson disease: A high-field (1) H-MR spectroscopy imaging study.
Seraji-Bozorgzad N; Bao F; George E; Krstevska S; Gorden V; Chorostecki J; Santiago C; Zak I; Caon C; Khan O
Mov Disord; 2015 Sep; 30(10):1400-4. PubMed ID: 26228901
[TBL] [Abstract][Full Text] [Related]
12. Metabolite ratios in the posterior cingulate cortex do not track cognitive decline in Parkinson's disease in a clinical setting.
Almuqbel M; Melzer TR; Myall DJ; MacAskill MR; Pitcher TL; Livingston L; Wood KL; Keenan RJ; Dalrymple-Alford JC; Anderson TJ
Parkinsonism Relat Disord; 2016 Jan; 22():54-61. PubMed ID: 26627939
[TBL] [Abstract][Full Text] [Related]
13. Proton magnetic resonance spectroscopic imaging in progressive supranuclear palsy, Parkinson's disease and corticobasal degeneration.
Tedeschi G; Litvan I; Bonavita S; Bertolino A; Lundbom N; Patronas NJ; Hallett M
Brain; 1997 Sep; 120 ( Pt 9)():1541-52. PubMed ID: 9313638
[TBL] [Abstract][Full Text] [Related]
14. Proton MR spectroscopic changes in Parkinson's diseases after thalamotomy.
Baik HM; Choe BY; Son BC; Jeun SS; Kim MC; Lee KS; Kim BS; Lee JM; Lee HK; Suh TS
Eur J Radiol; 2003 Sep; 47(3):179-87. PubMed ID: 12927660
[TBL] [Abstract][Full Text] [Related]
15. Assessment of metabolic changes in the striatum of a MPTP-intoxicated canine model: in vivo ¹H-MRS study of an animal model for Parkinson's disease.
Choi CB; Kim SY; Lee SH; Jahng GH; Kim HY; Choe BY; Ryu KN; Yang DM; Yim SV; Choi WS
Magn Reson Imaging; 2011 Jan; 29(1):32-9. PubMed ID: 20980117
[TBL] [Abstract][Full Text] [Related]
16. Posterior cingulate metabolic changes occur in Parkinson's disease patients without dementia.
Camicioli RM; Korzan JR; Foster SL; Fisher NJ; Emery DJ; Bastos AC; Hanstock CC
Neurosci Lett; 2004 Jan; 354(3):177-80. PubMed ID: 14700725
[TBL] [Abstract][Full Text] [Related]
17. Discrepant longitudinal volumetric and metabolic evolution of diffuse intrinsic Pontine gliomas during treatment: implications for current response assessment strategies.
Löbel U; Hwang S; Edwards A; Li Y; Li X; Broniscer A; Patay Z
Neuroradiology; 2016 Oct; 58(10):1027-1034. PubMed ID: 27438806
[TBL] [Abstract][Full Text] [Related]
18. Metabolic changes in de novo Parkinson's disease after dopaminergic therapy: A proton magnetic resonance spectroscopy study.
Ciurleo R; Bonanno L; Di Lorenzo G; Bramanti P; Marino S
Neurosci Lett; 2015 Jul; 599():55-60. PubMed ID: 26007705
[TBL] [Abstract][Full Text] [Related]
19. Application of proton magnetic resonance spectroscopy on substantia nigra metabolites in Parkinson's disease.
Zhou B; Yuan F; He Z; Tan C
Brain Imaging Behav; 2014 Mar; 8(1):97-101. PubMed ID: 23955491
[TBL] [Abstract][Full Text] [Related]
20. Proton MR spectroscopic imaging of the striatum in Parkinson's disease.
Cruz CJ; Aminoff MJ; Meyerhoff DJ; Graham SH; Weiner MW
Magn Reson Imaging; 1997; 15(6):619-24. PubMed ID: 9285801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
